Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
$33.79-2.06%
报价 2026-11-13
市值
$1.04B
EV
$1.07B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -21.5%
$18.15$43.04
筛选结果
pipeline · 2026-11-13Keep✗ 高增长✗ Cheap✓ GARP
GARP Pool: growth 10-30%, MC/GP <= 11
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | -0.77 → -0.55 | — |
| FY+32028-12 | 1.3x | -0.77 → -0.01 | — |
毛利率 77% · TTM 收入 $377M · 基数 EPS -0.77(调整后)
电话会信号
辅助标签Q3 20262026-11-05
扩产上调指引盈利拐点
指引 上调
信心 4
分析师 4
“We expect positive adjusted EBITDA for the fourth quarter, full year 2026 and full year 2027.”
原文引用(3)
- 扩产:as the volumes grow, we will have to add people in both facilities, Pittsburgh and Scottsdale.
- 上调指引:We are increasing our full year 2026 total revenue guidance from our prior range of $365 million to $375 million to $385 million to $395 million.
- 盈利拐点:We also expect adjusted EBITDA for the full year 2027 to be positive.
蓝色标签在暴涨研究中略有区分度;悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CSTLCastle Biosciences, Inc. | $1.04B | -2.1% | +15.6% | 77.1% | – | – | – | GARP |
| CDNACareDx, Inc | $4.09B | -2.4% | +40.1% | 71.1% | 32.6x | 141.7x | 71.0x | 高增长 |
| VIRVir Biotechnology, Inc. | $1.71B | -17.8% | +1488.5% | 97.2% | – | – | – | |
| PSNLPersonalis, Inc. | $1.7B | -0.9% | +19.4% | 21.2% | – | – | – | |
| AMNAMN Healthcare Services, Inc. | $1.47B | +1.6% | +26.5% | 30.6% | 17.4x | 6.4x | 4.1x | Cheap GARP |
| FLGTFulgent Genetics, Inc. | $689M | -0.8% | +3.3% | 33.8% | – | – | – | |
| GERNGeron Corporation | $623M | -2.7% | +26.3% | 66.7% | – | – | – | |
| EVHEvolent Health, Inc. | $551.2M | +2.7% | +40.8% | 12.9% | – | – | 31.9x | |
| MYGNMyriad Genetics, Inc. | $542.9M | -0.4% | -4.7% | 68.8% | – | – | – | |
| 同行中位数 | – | – | +26.4% | 50.3% | 25.0x | 74.1x | 31.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $103.5M | $83.7M | $87M | $83M | $86.2M | $88M | $86.3M | $85.8M |
| Gross Margin | 77.1% | 75.5% | 79% | 77.5% | 79.5% | 81.4% | 81.3% | 81.8% |
| Operating Margin | -3% | -22% | -4.4% | -8.2% | -4.9% | -31.7% | 4.7% | 5.9% |
| Net Income | $-2.1M | $-14.5M | $-2.3M | $-501,000 | $4.5M | $-25.8M | $9.6M | $2.3M |
| Diluted EPS | -0.07 | -0.49 | -0.08 | -0.02 | 0.15 | -0.9 | 0.32 | 0.08 |
| Operating Cash Flow | $15.2M | $-22.1M | $26.9M | $22.6M | $20.8M | $-6M | $24.4M | $23.3M |